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SUMMARY
The gastrointestinal (GI) epithelium is a highly regenerative tissue with the potential to provide a 
renewable source of insulin+ cells after undergoing cellular reprogramming. Here, we show that 
cells of the antral stomach have a previously unappreciated propensity for conversion into 
functional insulin-secreting cells. Native antral endocrine cells share a surprising degree of 
*Correspondence: qiao_zhou@harvard.edu. 
AUTHOR CONTRIBUTIONS
C.A. and Q.Z. conceived and designed the experiments and analyzed the results; C.A. performed most of the experiments; A.T., J.L., 
M.S.S., C.A.R., and D.T.B. helped design and perform the organoid experiments; G.X. and S.M. analyzed the microarray data and 
performed statistical analysis; C.V. and D.M. helped design and perform the bioengineered stomach experiments; R.A.S helped design 
the Cdx2 experiments; D.A.M., B.Z.S., D.M., R.A.S, Q.X, and D.T.B. contributed reagents/materials/analysis; and Q.Z. and C.A. 
wrote the paper. All authors discussed the manuscript.
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is GEO: GSE76686.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures, seven figures, and four tables and can be found with this 
article online at http://dx.doi.org/10.1016/j.stem.2016.01.003.
HHS Public Access
Author manuscript
Cell Stem Cell. Author manuscript; available in PMC 2017 March 03.
Published in final edited form as:













transcriptional similarity with pancreatic β cells, and expression of β cell reprogramming factors in 
vivo converts antral cells efficiently into insulin+ cells with close molecular and functional 
similarity to β cells. Induced GI insulin+ cells can suppress hyperglycemia in a diabetic mouse 
model for at least 6 months and regenerate rapidly after ablation. Reprogramming of antral 
stomach cells assembled into bioengineered mini-organs in vitro yielded transplantable units that 
also suppressed hyperglycemia in diabetic mice, highlighting the potential for development of 
engineered stomach tissues as a renewable source of functional β cells for glycemic control.
Graphical Abstract
INTRODUCTION
Major progress has been made in recent years to produce functional insulin+ cells for cell 
replacement therapies to treat diabetes. These regenerative technologies include directed 
differentiation of embryonic stem cells and direct conversion from non-β cells such as liver 
cells, acinar cells, and others (Hebrok, 2012; Johannesson et al., 2015; Nostro and Keller, 
2012; Schiesser and Wells, 2014; Zhou and Melton, 2008). However, because ongoing 
pathological conditions in diabetes inflict continued damage to native and transplanted β 
cells (Azzi et al., 2010; Butler et al., 2003; Lakey et al., 2006; Rahier et al., 2008), it is 
desirable to develop a regenerative system where β cells can be produced in a renewable 
fashion to counteract β cell loss. The gastrointestinal (GI) tissues are potential sources for 
such continued generation of β cells. The stomach and intestine are unique among 
endodermal organs in that they harbor large numbers of adult stem/progenitor cells that 
constantly produce epithelial cells, including hormone-secreting enteroendocrine cells 
(Barker et al., 2007, 2010; May and Kaestner, 2010; Schonhoff et al., 2004a). Both organs 
are developmentally related to the pancreas, arising in adjacent embryonic domains (Offield 
et al., 1996). Development of gut enteroendocrine and pancreatic endocrine cells also 
depends on common critical factors, such as Ngn3 (also known as Neurog3) (Gu et al., 
2002; Jenny et al., 2002; Lee et al., 2002). Recent studies showed that intestinal cells could 
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be converted into insulin+ cells with either endocrine-specific deletion of FoxO1 or 
ubiquitous expression of NPM reprogramming factors (Ngn3, Pdx1, and Mafa) (Bouchi et 
al., 2014; Chen et al., 2014; Talchai et al., 2012a). Although these studies revealed the 
feasibility of deriving β-like cells from the intestine, critical barriers remain in developing 
these approaches into future regenerative therapies. FoxO1 plays a critical role in protecting 
β cells from cellular stress (Kitamura et al., 2005; Talchai et al., 2012b), and deletion or 
suppression of FoxO1 in pancreatic β cells could result in β cell failure (Talchai et al., 
2012b; Talchai and Accili, 2015). Moreover, although NPM factors induce insulin+ cells in 
the intestine, the induced cells appear to lack certain important β cell genes such as Nkx6.1 
and exhibit reduced glucose responsiveness compared with pancreatic β cells (Chen et al., 
2014).
We sought to devise improved strategies to derive functional insulin-secreting (insulin+) 
cells from GI tissues and to harness the regenerative capacity of these tissues as a renewable 
source of β cells. We report the surprising finding that NPM factors reprogram 
enteroendocrine cells from the antral stomach more efficiently into functional insulin+ cells 
compared with enteroendocrine cells from the intestine. Induced antral insulin+ cells also 
express key β cell factors, including Nkx6.1 and Prohormone convertase 2 (PC2), which 
intestinal insulin+ cells lack. Our data reveal that native antral enteroendocrine cells share a 
surprising level of transcriptional similarity with pancreatic β cells. Further, the intestine-
specific Cdx2 gene can block efficient β cell reprogramming. Thus, intrinsic molecular 
differences between antral stomach and intestinal enteroendocrine cells could contribute to 
the differential reprogramming outcomes. To explore the therapeutic potential of gastric 
tissue as a source of inducible β cells, we created bioengineered stomach mini-organs; upon 
transplantation and sphere formation, these structures produced renewable insulin+ cells that 
reverse hyperglycemia in vivo. Our studies reveal antral stomach tissue as a previously 
unrecognized source that is highly amenable to reprogramming toward functional insulin+ 
cells. We also provide proof of principle evidence that bioengineered gastric tissue could 
serve as a renewable source of β cells for glycemic control.
RESULTS
NPM Factors Efficiently Reprogram GI Enteroendocrine Cells to Insulin+ Cells, with Antral 
Stomach Showing the Highest Induction Efficiency
Previous studies of reprogramming GI tissues to insulin+ cells have used either deletion of 
FoxO1 or expression of NPM factors (Ngn3, Pdx1, and Mafa). Surprisingly, no insulin+ 
cells were reported from stomach with either approach (Chen et al., 2014; Talchai et al., 
2012a). To revisit this important question, we performed additional reprogramming 
experiments in the GI tract. Using adenoviral infection of cultured mouse antral stomach 
organoids, we observed that the NPM factors are highly effective at inducing insulin 
expression whereas the other reprogramming factors tested, including Pax4, Insm1, Nkx6.1, 
and Mafa, are not effective (Figure S1). Based on this observation, we constructed new 
transgenic mouse lines (TetO-NPMcherry) in which the inducible TetO promoter drives 
polycistronic expression of NPM factors and the red fluorescent protein Cherry (Figure 1A). 
Global expression of NPM factors leads to rapid animal death due to hypoglycemia 
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(unpublished observations). To enable long-term observation and comparison of induced 
insulin+ cells from different GI regions, we targeted NPM factors to the GI enteroendocrine 
lineage, which shares molecular and developmental similarity with pancreatic endocrine 
cells (Habib et al., 2012; May and Kaestner, 2010; Schonhoff et al., 2004a), making it an 
excellent target for β cell conversion. We crossed the TetO-NPMcherry line with the 
bacterial artificial chromosome (BAC)-transgenic Ngn3-Cre line (Schonhoff et al., 2004b) 
and the knockin Rosa-floxed-rtTA line (Jackson Laboratory) to derive a triple-transgenic 
line we call NRT (Figure 1A). The well-described Ngn3-Cre line labels all enteroendocrine 
cells in the intestine and the majority of antral stomach enteroendocrine cells (Schonhoff et 
al., 2004b) (Figure S1).
After doxycycline (Dox) treatment of NRT animals for 10 days, we observed numerous 
insulin+ cells in the antral stomach and along the entire length of the intestine (Figures 1B–
1D, yellow arrows). The fundus region of the stomach contains relatively few Ngn3+ 
endocrine cells, and very few of these expressed insulin, suggesting that fundal cells resist 
NPM-mediated conversion (Figure S1). Quantitative analysis showed significantly higher 
reprogramming efficiency in the antrum (41.5% ± 8.5%, mean ± SD) than in the proximal 
(duodenum, 21.4% ± 6.7%), middle (ileum, 14.6% ± 3.3%), or distal (colon, 15.5% ± 3.4%) 
intestine (Figure 1E). The antral stomach also contains substantially higher levels of insulin 
protein compared with the intestine (Figure 1F), even though levels of reprogramming factor 
expression in fluorescence-activated cell sorting (FACS)-purified cherry+ cells from the 
antrum and different intestinal regions are comparable (Figure 1G).
Enteroendocrine cells in the stomach and intestine include multiple subtypes based on 
hormone expression (Habib et al., 2012; May and Kaestner, 2010; Schonhoff et al., 2004a). 
To evaluate whether insulin+ cells are preferentially induced in certain subtypes, we 
quantified seven major enteroendocrine subtypes before and after induction of insulin+ cells 
(Figure S1). All endocrine subtypes we examined were reduced upon doxycycline treatment, 
with the exception of serotonin+ cells, which do not originate from the Ngn3+ lineage 
(Schonhoff et al., 2004b) (Figure S1). These data indicate that insulin+ cells in both stomach 
and duodenum arise from multiple endocrine subtypes and/or their common progenitors. We 
also found the vast majority of induced GI insulin+ cells to be mono-hormonal (Figure S1). 
These data collectively show that NPM factors can robustly reprogram GI endocrine cells 
into insulin+ cells, with the highest reprogramming efficiency in the antral stomach.
Induced GI Insulin+ Cells Can Reverse Hyperglycemia Long-Term and Regenerate Rapidly 
upon Ablation
To test whether the induced GI insulin+ cells can secrete insulin and reverse hyperglycemia, 
we ablated pancreatic β cells in NRT mice with streptozotocin (STZ), which renders the 
animals hyperglycemic. Upon Dox treatment and induction of insulin+ cells in the GI tract, 
hyperglycemia was rapidly reversed and blood glucose levels remained normal for as long 
as we tracked them (Figure 2A, up to 6 months). In contrast to control animals, which died 
with hyperglycemia within 8 weeks, nearly every Dox-treated animal was rescued (Figure 
2B). Consistent with this effect, intraperitoneal glucose tolerance test (IPGTT) showed 
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substantial improvement after doxycycline induction (Figure 2C) and near-normal blood 
insulin level in STZ-ablated and Dox-induced animals (Figure 2D).
To confirm that rescue from hyperglycemia results from induction of insulin+ cells in the GI 
tract, we surveyed insulin expression in other Ngn3-expressing tissues including the brain, 
testis, and pancreas. No insulin+ cells were found in the brain or testis (data not shown). In 
the pancreas of NRT animals, STZ treatment led to near complete ablation of endogenous β 
cells (Figure S2), but Dox treatment induced insulin in glucagon+ cells, which comprise the 
majority of islet cells after β cell ablation (Figure S2). These glucagon+insulin+ cells do not, 
however, express other β cell factors such as Glut2 and Nkx6.1, and their insulin expression 
level is significantly lower than in native β cells (Figure S2). To assess the possibility that 
these glucagon+insulin+ cells may nevertheless contribute to reversal of hyperglycemia after 
Dox induction in NRT animals, we resected ~80% of the pancreas and thus most 
glucagon+insulin+ cells. No significant changes in blood glucose level followed (Figure 2A). 
The remnant 20% pancreas showed 0.15 ± 0.03 μg of total insulin (mean ± SD), 
significantly below the insulin content of antrum (1.89 ± 0.36 μg) or duodenum (1.20 ± 0.63 
μg; Figure S4). In comparison, a normal mouse pancreas contains ~10 μg insulin, although 
only a fraction of the β cell mass is required to maintain normoglycemia (Bonner-Weir, 
2000). These data collectively indicate that induced insulin+ cells from the GI tract are the 
main source of secreted insulin that led to long-term reversal of hyperglycemia.
The GI tract is a highly regenerative organ, with resident glandular stem cells continuously 
producing new epithelial cells (Barker et al., 2010; Barker et al., 2007). To evaluate the 
capacity of GI β cell regeneration from the stem cell compartment, we conducted a second 
round of STZ treatment (Figures 2A and 2E). Similar to pancreatic β cells, induced insulin+ 
cells from the antrum and intestine were sensitive to the toxin and disappeared, leading to 
hyperglycemia (Figures 2A and 2E). However, the diabetic state was again rapidly reversed, 
concomitant with the reappearance of GI insulin+ cells (Figure 2E). These data illustrate the 
high regenerative capacity of the genetically engineered GI tissues and their ability to 
sustain injuries and maintain suppression of hyperglycemia.
We also evaluated the lifespan of antral and intestinal insulin+ cells and their relative 
contributions toward glycemic control (Figure S3). In a pulse-chase experiment, GI insulin+ 
cells were first induced by Dox treatment, followed by Dox withdrawal. Intestinal insulin+ 
cells disappeared within 7 days, whereas stomach insulin+ cells persisted for more than 20 
days, consistent with estimated turnover rates of the native intestinal and antral epithelia 
(Karam and Leblond, 1993; Lehy and Willems, 1976; Messier and Leblond, 1960; 
Thompson et al., 1990). Antral insulin+ cells continued to suppress hyperglycemia after 
intestinal insulin+ cells had disappeared (Figure S3). Thus, antral insulin+ cells have a longer 
lifespan than their intestinal counterparts and can suppress hyperglycemia independently.
Antral Insulin+ Cells Bear Close Molecular and Functional Resemblance to Pancreatic β 
Cells
Immunohistochemistry revealed that induced insulin+ cells from the antral stomach and the 
proximal and distal intestine all express β cell factors such as c-peptide, glucose transporter 
2 (Glut2, or Slc2a2), prohormone convertase 1/3 (PC1/3), and Pax6 (Figure 3A, 
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quantification shown in Figure S4). However, other key β cell genes, including Nkx6.1, 
Nkx2.2, and prohormone convertase 2 (PC2), are expressed exclusively or predominantly in 
antral insulin+ cells (Figure 3A, quantitation shown in Figure S4). qPCR analysis further 
confirmed that many β cell factors are expressed at substantially higher levels in antral 
insulin+ cells than in duodenal or colonic insulin+ cells (Figure S4). Endogenous Pdx1, but 
not endogenous Mafa, is expressed in the native duodenum and antrum (Figure S4), as 
previously reported (Habib et al., 2012; Offield et al., 1996). Endogenous Mafa is activated 
strongly in antral insulin+ cells, but only weakly in duodenal and colonic insulin+ cells 
(Figure S4), whereas endogenous Pdx1 is induced in both antral and intestinal insulin+ cells 
(Figure S4). In contrast, endogenous Ngn3 is not induced (Figure S4). We observed 
continued expression of FoxO1 expression in both antral and intestinal insulin+ cells (Figure 
S4).
To assess functional properties of induced insulin+ cells from the stomach and the intestine, 
we harvested whole epithelial tissues from the antrum, duodenum, and colon of NRT 
animals after 10 days of Dox treatment. In vitro glucose-stimulated insulin secretion assays 
were performed with each sample at low-glucose (1.7 mM) and high-glucose (20.2 mM) 
conditions. Our data showed that although all GI insulin+ cells can respond to high glucose 
(Figure 3B), the responsiveness of antral insulin+ cells is significantly higher than that of 
duodenal and colonic insulin+ cells (Figure 3B; data standardized as high-glucose versus 
low-glucose response ratio: 3.02 ± 0.55 for antrum, 1.65 ± 0.37 for duodenum, and 1.61 ± 
0.46 for colon).
To further evaluate the function of induced GI insulin+ cells, we tested their physiological 
response to glibenclamide (Glib), an anti-diabetic drug that binds to Sur1 and inhibits the 
ATP-sensitive potassium channel in β cells. Glib treatment led to insulin release from antral, 
but not from duodenal or colonic, insulin+ cells (Figure 3C). Conversely, treatment with 
Diazoxide (Dzx), a potassium channel activator, suppressed insulin release from antral 
insulin+ cells, whereas duodenal and colonic cells showed no response (Figure 3C). 
Moreover, antral insulin+ cells responded to exendin-4, an antidiabetic drug that activates 
glucagon-like-peptide receptor (Glp1R), leading to increased insulin release at high glucose 
concentrations (Figure 3D), whereas duodenal and colonic insulin+ did not respond (Figure 
3D). Consistent with these physiological data, antral insulin+ cells express significantly 
higher levels of Sur1 and Glp1R, compared with duodenal and colonic insulin+ cells (Figure 
S4).
Thus, molecular and physiological studies together indicate that antral endocrine cells can be 
reprogrammed efficiently into insulin+ cells that resemble pancreatic β cells, whereas 
conversion from intestinal endocrine cells is comparatively incomplete.
Native Antral Endocrine Cells Share Substantial Transcriptional Similarity with Pancreatic 
β Cells
What mechanisms might underlie the significant difference? One long-standing hypothesis 
postulates that the more transcriptional and epigenetic similarities two cells share, the easier 
it is to interconvert them (Graf and Enver, 2009; Gurdon and Melton, 2008). Transcriptional 
studies of specific intestinal endocrine populations have been reported (Egerod et al., 2012; 
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Habib et al., 2012), but transcriptomes of antral endocrine cells remain uncharacterized. We 
therefore profiled the transcriptomes of enteroendocrine cells from the antrum, duodenum, 
and colon and assessed their similarity to pancreatic β cells. We used Ngn3-GFP reporter 
mice to isolate enteroendocrine cells from the different GI regions (Lee et al., 2002); Ngn3 
expression in the gut is transient and restricted to endocrine progenitors (Jenny et al., 2002; 
Lee et al., 2002). Ngn3-GFP labels a mixture of chromogranin− (Chga−) and chromogranin+ 
(Chga+) cells, representing immature and mature endocrine cells, respectively (Lee et al., 
2002) (Figure 4A). Our quantitation showed that the relative proportions of GFP+Chga− and 
GFP+Chga+ cells are comparable in antral stomach, duodenum, and colon (Figure S5). 
GFP+ cells purified by FACS from the different GI regions (Figure 4B) constitute ~1%–2% 
of the total cell population (Figure 4B), consistent with the estimated prevalence of gut 
endocrine cells (Schonhoff et al., 2004a).
We generated global transcriptome data from the purified cells with Illumina arrays. 
Comparative analyses showed that endocrine cells from the proximal and distal intestine are 
more similar to each other and less similar to antral endocrine cells (Figure S5, Spearman 
correlation coefficients: 0.91 [duodenum versus colon], 0.82 [antrum versus duodenum], and 
0.80 [antrum versus colon]). The overall similarity of proximal and distal intestine endocrine 
cells is high and consistent with published studies (Egerod et al., 2012; Habib et al., 2012) 
(1,470 differentially expressed genes listed in Table S3). We performed pairwise 
comparison of the three GI endocrine populations with our published transcriptome data of β 
cells, which was obtained by FACS purification from the islets of MIP-GFP animals (Li et 
al., 2014b). This analysis showed overall higher transcriptional similarity between antral and 
β cells than between intestinal and β cells (Figures 4C and S5, Spearman correlation 
coefficients: 0.72 [antrum versus β], 0.57 [duodenum versus β], and 0.57 [colon versus β]; 
Steiger’s Z-test for dependent correlations: p = 6.5 × 10−185). Thus, although 
enteroendocrine cells from the antrum, duodenum, and colon are more similar to each other 
than they are to pancreatic β cells, β cells appear to share more transcriptional similarity with 
antral enteroendocrine cells than intestinal enteroendocrine cells.
To evaluate the expression of β cell-enriched genes in GI enteroendocrine cells, we focused 
analysis on a collection of 2,398 genes that show higher expression in β cells than in acinar 
cells (Li et al., 2014b). Antral enteroendocrine cells showed higher expression of many β 
cell-enriched genes (Figure 4D, group 2 and 3 genes; Table S2) compared with intestinal 
enteroendocrine cells. In particular, many genes critical for β cell development and function, 
such as Nkx6.1, Nkx2.2, NeuroD1, Isl1, Rfx6, Insm1, Sur1 (ABCC8), and Glucokinase 
(GCK), are enriched in antral, compared with duodenal or colonic, enteroendocrine cells 
(Figures 4E and S5). Immunohistochemistry showed Nkx6.1 expression in a subset of antral 
GFP+ cells (24.9% ± 3.5%, mean ± SD), but not in the duodenum or colon (Figure 4F). The 
vast majority of antral Nkx6.1+ cells also express Chga (94.7% ± 3.1%) (Figures 4F and 
S5). Nkx2.2 is expressed in a majority of GFP+ cells in the antrum (57.2% ± 4.7%), but only 
in a minority of duodenal (18.7% ± 2.7%) or colonic (23.4% ± 4.3%) Chga+ cells (Figure 
4F). Most Nkx2.2+ cells express Chga (69.4% ± 3.4%, 64.0% ± 5.1%, and 65.5% ± 8.3% in 
antrum, duodenum, and colon, respectively) (Figure 4F; Figure S5). Gene Ontology analyses 
show that whereas enteroendocrine cells from all GI regions are enriched for pathways 
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involved in regulation of hormone secretion, G-protein-coupled receptor signaling, and 
vesicle-mediated transport, antral enteroendocrine cells are enriched specifically for the 
“glucose homeostasis” module (Figure S5; Table S2). Together, these studies reveal a 
surprising intrinsic difference between endocrine cell populations from the antral stomach 
and intestine, which likely contributes to their differential capacity for β cell reprogramming.
The Intestine-Specific Gene Cdx2 Can Inhibit β Cell Conversion
In a prior study of acinar to β cell conversion, we showed that persistent expression of acinar 
cell fate regulators Ptf1a and Nr5a2 blocks acquisition of β cell fate (Li et al., 2014c). Cdx2 
is an intestine-specific master regulator gene (Gao et al., 2009), and its persistent expression 
in intestinal insulin+ cells (Figure 5A) raises the question of whether Cdx2 might block 
intestinal cells from adopting more complete β cell features. To test this hypothesis, we 
generated epithelial organoids from the antrum and duodenum of double transgenic Rosa-
rtTA;TetO-NPMcherry (Rosa-NPM) animals and treated them with Dox in culture. Similar 
to our observations in vivo, antral organoids produced more C-peptide+ cells with higher 
levels of β cell factors compared with intestinal organoids (Figure S6). Next, we expressed 
either the control cherry gene or Cdx2 using adenoviral infection in the double-transgenic 
antral organoids (Figures 5B and 5C), followed by treatment with Dox to activate β cell 
conversion. Cdx2 significantly suppressed expression of multiple β cell genes, including 
NeuroD1, Nkx2.2, and Nkx6.1 (Figure 5D).
To further evaluate the role of Cdx2 in intestine reprogramming, we deleted Cdx2 from 
duodenal organoids. We established duodenal organoids from animals where a single allele 
or both alleles of the Cdx2 gene are floxed (Figure 5E, Cdx2fl/+ and Cdx2fl/fl). Infection with 
an polycistronic adenovirus expressing NPM factors and the Cre recombinase (pAd-
NPM.Cre) led to simultaneous removal of the floxed Cdx2 allele(s) and expression of NPM 
factors (Figure 5E). Immunohistochemistry and qPCR confirmed complete removal of Cdx2 
from the majority of Cdx2fl/fl duodenal cells (Figures 5E and 5F). Cdx2 deletion 
significantly enhanced expression of several β cells genes, including Insulin1, insulin2, 
Nkx6.1, and NeuroD. These data together suggest that Cdx2 acts as a molecular barrier to β 
cell conversion; thus, failure to downregulate Cdx2 in intestinal insulin+ cells likely 
contributes to their incomplete acquisition of β cell properties.
Constructing Bioengineered Stomach and Intestine Mini-organs to Produce Insulin+ Cells
Among GI tissues, antral stomach is a superior source of functional β cells by NPM-
mediated conversion, and antral insulin+ cells are rapidly replenished from the native stem 
cell compartment. However, inducing β cells from the native GI tract in situ may have 
limitations in therapy, because the native endocrine populations regulate many physiologic 
processes (Field et al., 2010; May and Kaestner, 2010; Schonhoff et al., 2004a), and 
diverting them into β cells may disrupt normal endocrine homeostasis. Moreover, induced β 
cells positioned along the native GI epithelium may inadvertently respond to dietary as well 
as blood glucose. To circumvent these potential barriers to therapeutic application, we 
studied the feasibility of constructing “stomach mini-organs” that contain genetically 
engineered antral tissues as a reservoir of new β cells.
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Following published protocols on bioengineering stomach (Maemura et al., 2004; Speer et 
al., 2011), we embedded gastric gland units from the antrum of CAGrtTA∷TetO-
NPMcherry (CAG-NPM) animals in Matrigel, loaded them onto poly(glycolic acid) (PGA) 
scaffolds, and transplanted the material into the omental flap of immunodeficient NSG 
recipient animals (Figures 6A–6C). Four weeks later, bioengineered stomach spheres 
measuring 0.5 to 1 cm in diameter formed outside the native gut (Figure 6D). By histology, 
5 out of 15 such spheres showed robust epithelial reconstitution, while the others showed 
little or no epithelium (Figure S7). Antral glands in the native stomach are composed largely 
of mucous and endocrine cells and lack acid-secreting parietal cells. The engineered 
stomachs also showed a simple organization, with one or several layers of Ecadherin+ cells 
surrounded by connective tissue (Figure S7). The epithelial component contained Sox9+ 
stem/progenitor cells (Furuyama et al., 2011), Mucin5+ secretory cells, and Chga+ endocrine 
cells (Figure S7). In parallel, we used a similar bioengineering approach to construct 
“intestine mini-organs” using duodenal gland units. The success rate for epithelial 
reconstitution was lower in intestinal spheres (3 out of 15), which contained Muc2+ 
secretory cells and Chga+ endocrine cells, similar to the native duodenal epithelium. Our 
observations are consistent with other published studies on bioengineered stomach and 
intestine (Maemura et al., 2004; Speer et al., 2011).
To evaluate induction of insulin+ cell in the engineered stomach and intestine spheres, we 
administered Dox for 2 weeks. Many insulin+ cells appeared in the epithelial layer of 
stomach as well as intestinal spheres. The stomach spheres had significantly more insulin+ 
cells, higher reprogramming efficiency, and higher insulin content per milligram of tissue 
(Figures 6E, 6L, 6P, and 6Q). The majority of stomach insulin+ cells express Nkx6.1, Glut2, 
and PC1/3, whereas intestine insulin+ cells lack Nkx6.1 and have reduced PC1/3 expression 
(Figures 6F–6H, 6M–6O, and 6R).
Transplanted Stomach Mini-organs Can Control Hyperglycemia in Diabetic Mice
To assess if β cells induced in the engineered stomachs could release functional insulin, we 
ablated pancreatic β cells in transplanted animals using STZ and then induced insulin+ cells 
in the engineered stomach spheres by administering Dox (Figure 7A). Of the 22 treated 
animals, 5 showed sustained decreases in blood glucose levels after Dox treatment (group 
1), whereas the others remained hyperglycemic (group 2) (Figure 7B). We monitored 
animals for 6 weeks and subsequently removed the grafted stomach spheres from G1 mice, 
which restored hyperglycemia (Figure 7B). Engineered stomach spheres from G1 animals 
showed good epithelial structures containing many insulin+ cells (Figure S7), whereas 
spheres from the G2 groups showed limited epithelial structures with few insulin+ cells 
(Figure S7). Consistent with the glucose monitoring data and histology, G1 animals showed 
improved responses to intraperitoneal glucose challenge (Figure 7C). Blood insulin levels in 
G1 animals also were substantially higher than in G2 animals (Figure 7D).
Immunohistochemistry revealed PEcam+ blood vessels closely associated with insulin+ cells 
in engineered stomach spheres (Figure 7E), consistent with previous observations that 
induced β cells, similar to endogenous β cells, can secrete VEGF and remodel local 
vasculature (Zhou et al., 2008). Moreover, large numbers of Sox9+ stem/progenitor cells and 
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Ki67+ proliferating epithelial cells are present in the engineered stomach spheres before and 
after Dox treatment, indicating persistence of a stem/progenitor compartment (Figures 7F 
and 7G). These studies collectively indicate that induced insulin+ cells from the 
bioengineered stomach spheres can release insulin into the circulation and regulate blood 
glucose levels.
DISCUSSION
The GI tract is a highly regenerative endodermal organ. We sought to harness this 
regenerative capacity to create a renewable source of functional insulin+ cells by NPM-
mediated reprogramming. Our data show that antral stomach enteroendocrine cells are 
converted to insulin+ cells more efficiently than intestinal enteroendocrine cells and possess 
molecular and functional hallmarks of pancreatic β cells. Thus, the antral stomach is a 
surprisingly good source for reprogrammed insulin+ cells, and we demonstrate the 
application of bioengineered stomach spheres to control blood glucose levels.
Expression of NPM factors previously led to formation of insulin+ cells in the intestine 
(Chen et al., 2014). Our experimental system is similar to this previous report and confirms 
induction of insulin+ cells in the intestine with incomplete β cell conversion. In contrast, 
antral stomach endocrine cells are more fully reprogrammed, with robust expression of key 
β cell genes and substantially improved glucose responsiveness. Our studies suggest that the 
difference can be attributed, at least in part, to intrinsic molecular differences between antral 
and intestinal enteroendocrine cells. Higher levels of β cell fate regulators in antral 
enteroendocrine cells may facilitate their conversion, whereas Cdx2, which is specifically 
expressed in all intestinal, but not stomach, cells inhibits conversion. It is notable that Cdx2 
expression persists in induced insulin+ intestinal cells. Prior studies have shown that ectopic 
Cdx2 expression in stomach promotes an intestine fate (Silberg et al., 2002; Verzi et al., 
2013), whereas Cdx2 loss in cultured intestinal organoids activates antral differentiation 
(Simmini et al., 2014). Continued expression of Cdx2 in intestinal insulin+ cells may thus 
present a molecular barrier for complete reprogramming.
Compared with the gastric antrum, the gastric corpus contains few Ngn3-derived 
enteroendocrine cells, and few such cells expressed insulin after NPM induction. Global 
expression of NPM factors also induced few insulin+ cells in the fundus (Figure S1). Thus, 
gastric corpus endocrine cells, which are distinct from those in the antrum or intestine (Choi 
et al., 2014; Li et al., 2014a) and mainly derive from Ngn3-independent lineages (Li et al., 
2014a; Schonhoff et al., 2004b), are not amenable to NPM-mediated β cell conversion. What 
might account for this resistance? The antral stomach shares a close developmental origin 
with the pancreas, with both organs arising from a common Pdx1+ endodermal domain 
during embryogenesis (Wells and Melton, 1999). Therefore, we speculate that the epigenetic 
landscape of endocrine cells from the fundus is more distinct than those from the antrum, 
making them harder to convert into β cells. Future studies will be necessary to understand 
these regional distinctions.
FoxO1 deletion also leads to formation of insulin+ cells in the intestine, suggesting a 
therapeutic path toward inducing insulin+ cells in situ (Bouchi et al., 2014; Talchai et al., 
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2012a). Our approach offers several advantages. First, with our method, induced insulin+ 
cells preserve FoxO1 function, which is known to protect β cells from physiologic stress 
(Kitamura et al., 2005; Talchai et al., 2012b). Second, with bioengineered stomach spheres, 
native endocrine cell populations in the gut remain undisturbed, and their functions in 
physiology are preserved. Third, by separating engineered stomachs from the native organ, 
induced β cells can be positioned to respond only to changes in blood and not luminal 
glucose levels.
In summary, our study offers a new approach to harness the intrinsic regenerative capacity 
of the stomach epithelium to replenishing β cell mass in vivo. Given ongoing pathological 
insults that continuously erode native or transplanted β cells in diabetes, long-term treatment 
may require repeated transplants. The regenerative system we propose could eliminate that 
need, and the number and size of transplanted stomach spheres could be manipulated to 
control β cell numbers. Coupled with recent progress in genome engineering and the ready 
access to human gastric epithelium from biopsies and differentiated induced pluripotent 
stem cells or embryonic stem cells (McCracken et al., 2014), the therapeutic applications of 
this approach are considerable.
EXPERIMENTAL PROCEDURES
Mouse Strains
R26-floxed-rtTA, R26-floxed-GFP, R26-rtTA, CAG-rtTA, Ngn3-Cre, and NSG mouse 
strains were obtained from The Jackson Laboratory. Ngn3-GFP (Gu et al., 2002; Jenny et 
al., 2002; Lee et al., 2002) and Cdx2fl/fl (Silberg et al., 2002; Verzi et al., 2013) mice have 
been described previously. The TetO-NPMcherry mouse lines were made by standard 
pronuclear injection at the Harvard Genomic Modification Facility (Cambridge, MA). All 
animal experiments are approved by the Harvard Institutional Animal Care and Use 
Committee.
Antibodies and Immunofluorescence
Tissues were processed as previously described (Li et al., 2014b). Primary antibodies are 
listed in Supplemental Experimental Procedures. Pictures were taken with a Zeiss LSM 510 
META confocal microscope. For quantification of marker+ cells such as insulin+ cells, a 
total of at least 1,000 Marker+ were analyzed from tissues harvested from three different 
animals. Typically, at least ten randomly selected sections were counted per animal.
FACS Isolation of GFP+ Cells and Gene Profiling
To dissociate tissues into single cells for FACS purification, we modified published 
protocols (Habib et al., 2012; Reimann et al., 2008; Talchai et al., 2012a). See Supplemental 
Experimental Procedures for details. GFP+ cells were isolated by FACS with FACSaria (BD 
Bioscience). Transcriptome data were generated with Illumina microarrays (Sentrix 
BeadChip MouseRef-8 v2 Arrays) that contain probes for ~19,000 genes. Data analysis, 
including statistical methods used, is described in Supplemental Experimental Procedures.
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Glucose Stimulated Insulin Secretion Assay and Drug Treatments
Isolation of gastrointestinal epithelial cells was carried out as previously described with 
slight modifications (Habib et al., 2012; Reimann et al., 2008; Talchai et al., 2012a). Briefly, 
antrum tissue was cut into small pieces and incubated in 10 mM EDTA for 30 min, followed 
by mechanical dissociation to extract cell clusters. To collect duodenal samples, the 
duodenum tissue was first cut into small pieces, incubated in 10 mM EDTA for 5 min, and 
mechanically stripped to release the villi. Each cell fraction was incubated with Krebs 
Ringer buffer supplemented with 1.7 mM or 20.2 mM glucose, glibenclamide (10 nM; 
Tocris), diazoxide (0.5 mM; Sigma), or exendin-4 (100 nM; Sigma). Released insulin 
amounts were determined by ELISA (Alpco) at the Joslin Specialized Assay core (Joslin 
Diabetes Center, Boston). Data from different tissue sources were standardized according to 
basal insulin release level. Each standardized sample is equivalent to 1/15 of antrum or 5 
mm of duodenum, or 10 mm of colon in a single animal.
Physiological Studies
Diabetic animals were produced with intraperitoneal injection of STZ (150–170 mg/kg) in 
6- to 8-week-old animals. Animals that displayed >400 mg dl−1 blood glucose levels for 2 
consecutive days after STZ administration were used for experiments. Blood glucose was 
measured with an Ascensia Elite glucometer (Bayer). For blood glucose monitoring, a short 
2-hr fasting precedes glucose measurements. Glucose tolerance test was performed with 
intraperitoneal injection of 1 mg/g body weight of glucose, preceded by 4-hr fasting. Blood 
insulin was collected from tail vein blood sampling and measured by ELISA. Tissue insulin 
was extracted with acid-ethanol solutions and measured by ELISA.
Organoid Culture and Adenoviral Infection
Antral stomach and duodenal organoids were derived from young adult mice (1–2 months) 
and cultured using standard growth media, essentially as described (Barker et al., 2010). To 
test β cell reprogramming factors, 4- to 7-day cultures of antral or duodenal organoids were 
recovered from the Matrigel with the recover solution (Corning), infected with purified 
adenovirus at 4 ×107 plaque-forming units (PFU) in 100 μl medium for 1 hr at 37°C and re-
embedded in Matrigel. qPCR analysis was performed 6–8 days after infection.
Generation of Bioengineered Stomach and Intestine
Generation of bioengineered stomach and stomach spheres was performed essentially as 
described previously (Maemura et al., 2004; Speer et al., 2011). See Supplemental 
Experimental Procedures for further details.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• Antral stomach cells reprogram effectively to insulin+ pancreatic β-like cells
• Antral endocrine cells are transcriptionally related to pancreatic β cells
• Induced insulin+ cells reverse hypoglycemia after transplantation in diabetic 
mice
• Reprogrammed cells in bioengineered mini-organs give functional rescue in 
vivo
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Figure 1. NPM Factors Efficiently Reprogram Gastrointestinal Endocrine Cells to Insulin+ Cells 
with the Highest Induction Efficiency in Antral Stomach
(A) Diagram of the triple-cross transgenic mouse line, referred to as NRT (Ngn3-Cre; Rosa-
floxed-rtTA; Teto-NMPcherry). Ngn3-cre is used to target inducible expression of the NPM 
factors (Ngn3, Pdx1, and Mafa) into the enteroendocrine cells of the antral stomach and the 
intestine. Black bars in Teto-NPMcherry indicate 2A peptides used to mediate polycistronic 
expression.
(B–G) Doxycycline treatment of NRT animals yielded many insulin+cherry+ cells from the 
antral stomach (B), the duodenum (C), and the colon (D), among other GI regions. 
Quantitation showed a higher induction efficiency of insulin+ cells in antrum compared with 
duodenum (du), ileum (IL), and colon (Co) (E, n = 3 animals, p = 0.0026). Antrum tissue 
also has higher insulin content (F, n = 3 animals, p = 0.0046). Using FACS-purified cherry+ 
cells, the expression level of transgenes in the endocrine population was found to be 
comparable (G), n = 3 animals). Scale bar, 100 μm. Yellow arrows indicate insulin+cherry+ 
cells; white arrowheads indicate insulin−cherry+ cells.
See also Figure S1.
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Figure 2. Induced Insulin+ Cells from the GI Tract Can Reverse Hyperglycemia Long-Term and 
Regenerate Rapidly
(A) Glucose monitoring of hyperglycemic NRT animals over 6 months. Streptozotocin 
(STZ) was used to ablate endogenous pancreatic β cells and create hyperglycemia. 
Doxycycline (Dox) was administered continuously from week 1 onward (red line). 
Compared with persistent hyperglycemia and death of control animals (–Dox group, black 
squares), Dox treatment led to long-term suppression of hyperglycemia (+Dox group, red 
circles). A second round of STZ ablation was conducted at week 10 to evaluate the 
regenerative capacity of this experimental system. The ensuing hyperglycemia was 
suppressed again by week 13. Pancreatectomy was performed on week 19 to remove ~80% 
of the pancreas. No significant effect on blood glucose levels was observed.
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(B–D) Dox treatment and induction of insulin+ cells led to significant improvement in the 
survival of hyperglycemic NRT animals (B, n = 12 animals in each group). Glucose 
tolerance tests showed near-normal responses for Dox-treated animals (C, n = 4 animals in 
each group). The blood insulin levels of the induced animals are comparable with that of 
wild-type animals and significantly higher than non-induced animals (D, n = 4 animals in 
each group, p < 0.001).
(E) Immunohistochemistry showed before and after induction of insulin+ cells (first and 
second panel, respectively). STZ treatment was used at week 11 to ablate the induced 
insulin+ cells from the GI tract (third panel). Insulin+ cells were regenerated rapidly 3 weeks 
later (last panel). Ki67 staining labels the proliferating stem/progenitor cell compartment at 
the base of the glands. Scale bar, 100 μm.
All quantitative data presented as mean ± SD. Statistical significance was evaluated with the 
Student’s t test (***p < 0.001). See also Figures S2 and S3.
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Figure 3. Induced Insulin+ Cells from the Antral Stomach More Closely Resemble β Cells 
Molecularly and Functionally
(A) Immunohistochemistry showed that induced insulin+ cells from the antrum express β 
cell genes Nkx6.1, Nkx2.2, and Prohormone convertase 2 (PC2), which are largely absent 
from duodenum and colon insulin+ cells. In contrast, Prohormone convertase 1/3 (PC1/3), 
glucose transporter 2 (Glut2), and c-peptide (c-ppt) are expressed commonly in antral, 
duodenal, and colonic insulin+ cells. Arrows indicate antral insulin+ that are PC2+, Nkx2.2+, 
and Nkx6.1+. Scale bar, 50 μm.
(B) Glucose stimulated insulin secretion (GSIS) in vitro. Antral tissues have significantly 
higher glucose responsiveness, defined as fold increase of insulin release at high versus low 
glucose conditions, compared with duodenal and colonic tissues (n = 8, p < 0.001).
(C and D) The antidiabetic drug Glibenclamide (Glib) stimulated insulin release from the 
antral insulin+ cells whereas Diazoxide (Dzx), a suppressor of insulin release, reduced antral 
insulin secretion (C, n = 4). In contrast, duodenal and colonic insulin+ cells do not respond 
to Glib or Dzx (C). Antral insulin+ cells also respond to Exendin-4 (Ex4) with enhanced 
insulin secretion at high glucose levels whereas duodenal and colonic cells do not respond to 
Exendin (D, n = 4).
All quantitative data presented as mean ± SD. Statistical significance was evaluated with the 
Student’s t test (*p < 0.05, **p < 0.01, and ***p < 0.001). See also Figure S4.
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Figure 4. Enteroendocrine Cells of the Antral Stomach Share Substantial Transcriptional 
Similarity with Pancreatic β Cells
(A) Immunohistochemistry showing distribution of GFP+ in the GI tract of the Ngn3-GFP 
mouse line. The GFP+ cells include both relatively immature (GFP+Chromogranin−) and 
more mature enteroendocrine cells (GFP+Chromogranin+). Scale bar, 50 μm.
(B and C) Ngn3-GFP+ cells were purified by FACS from antrum, duodenum, and colon (B). 
Scatterplots of transcriptome comparisons between pancreatic β cells and the GI 
enteroendocrine populations (C). Antral enteroendocrine cells show a greater similarity with 
β cells.
(D and E) Analysis of 2,398 β cell-enriched genes showed a general trend of elevated 
expression in antral enteroendocrine cells compared with duodenal and colonic 
enteroendocrine cells (D). In particular, antral enteroendocrine cells share a group of genes 
(group 2) with β cells (D) that are enriched for factors important in β cell development and 
function (E). Quantitative data presented as mean ± SD. Statistical significance was 
evaluated with the Student’s t test (*p < 0.05, **p < 0.01, and ***p < 0.001).
(F) Immunohistochemistry showed that Nkx6.1 is present in a population of Chga+ 
enteroendocrine cells in the antrum, but not expressed in duodenum or colon (top, arrows). 
Nkx2.2 is expressed in a majority of Chga+ enteroendocrine cells in the antrum and a 
minority of Chga+ cells in the duodenum and colon (F, bottom, arrows). Scale bar, 50 μm.
See also Figure S5.
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Figure 5. The Intestine-Specific Cell Fate Regulator Cdx2 Can Inhibit β Cell Conversion
(A) Duodenal and colonic insulin+ cells express Cdx2, the master regulator of intestine cell 
fate whereas antral stomach cells do not express Cdx2 before or after induction in NRT 
animals. Scale bar, 50 μm.
(B–D) Epithelial organoids were established from antral tissues of double-transgenic Rosa-
rtTA;Teto-NPMcherry (Rosa-NPM) animals and infected with either control adenovirus 
expressing Cherry (pAd-cherry) or adenovirus expressing Cdx2 and Cherry (pAd-
Cdx2.cherry) (B and C). Dox treatment was subsequently used to induce β cell conversion in 
these antral organoids. qPCR analysis showed that ectopic Cdx2 suppressed the expression 
of multiple β cell genes (D, n = 3). Scale bar, 100 μm.
(E–G) Duodenal organoids were established from Cdx2fl/+ and Cdx2fl/fl animals (E, left and 
right, respectively). Infection with an adenovirus co-expressing both NPM factors and the 
Cre recombinase led to simultaneous deletion of floxed Cdx2 allele and expression of NPM 
factors (E). Complete removal of Cdx2 was observed in majority of Cdx2fl/fl duodenal cells 
by immunohistochemistry and qPCR analysis (E and F) and led to enhanced expression of 
multiple β cell genes from the duodenal organoids (G, n = 3). Scale bar, 100 μm.
Quantitative data presented as mean ± SD. Statistical significance was evaluated with the 
Student’s t test (*p < 0.05, **p < 0.01, and ***p < 0.001). See also Figure S6.
Ariyachet et al. Page 22













Figure 6. Construction of Bioengineered Stomach and Intestine Mini-organs to Produce Insulin+ 
Cells
(A–K) Schematic diagram of engineering stomach and intestine mini-organs (A). Gastric or 
intestinal units were isolated from the antrum or duodenum of CAG-NPM (Cag-rtTA∷TetO-
NPMcherry) animals (B and I) and loaded onto polyglycolic acid scaffolds (C and J). The 
scaffolds were placed inside the omental flap of recipient immune-deficient NSG animals. 4 
weeks later, an engineered stomach (E. St) or intestine (E. Int) sphere formed (D and K, 
circled tissue). Scale bars represent 400 μm (B and I) and 6 μm (C and J).
(E–R) In engineered stomach and intestine spheres where reconstitution of epithelium was 
successful, Dox treatment led to induction of many insulin+ cells (E and L). The induction 
efficiency is higher for stomach tissues (P, n = 3). Stomach tissues also have higher insulin 
content (Q, n = 3). The majority of insulin+ cells from engineered stomach express Nkx6.1, 
PC1/3, and Glut2 (F, G, H, and R) whereas insulin+ cells from engineered intestine lack 
Nkx6.1 and have reduced PC1/3 expression (M, N, O, and R). Quantitation presented as 
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mean ± SD. Statistical significance was evaluated with the Student’s t test (**p < 0.01 and 
***p < 0.001).
See also Figure S7.
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Figure 7. Transplanted Stomach Mini-organs Can Reverse Hyperglycemia in Diabetic Mice
(A) Diagram of the experimental design. STZ treatment was used to ablate endogenous β 
cells in NSG animals transplanted with 4-week-old stomach spheres, followed by 
continuous Dox treatment of induce insulin+ cells. At the end of the experiment, the 
engineered stomachs were removed surgically.
(B–D) STZ treatment led to rapid hyperglycemia that persists in the absence of treatment 
(−Dox group, n = 6, black squares) (B). After Dox treatment, a group of five animals 
showed prolonged suppression of hyperglycemia (G1 animals, n = 5, red squares), whereas 
another group of animals remained hyperglycemic (G2 animals, n = 17, blue squares) (B). 
After 6 weeks, the engineered stomach spheres were removed from the G1 animals, which 
led to their reversal back to hyperglycemia (B). G1 animals showed improved response in 
glucose tolerance test (C, n = 4) and substantially higher blood insulin levels (D, n = 4) 
compared with G2 animals or control STZ-treated animals without Dox induction. Wilde-
Ariyachet et al. Page 25













type control animals in (C) (green squares) are non-STZ-treated animals with intact 
pancreatic β cell mass. Quantitative data presented as mean ± SEM. Statistical significance 
was evaluated with the Student’s t test (***p < 0.001).
(E–G) Sox9+ and Ki67+ cells are present in the engineered stomach after 4-week Dox 
treatment (E and F), indicating persistence of stem/progenitor cells. PEcam+ blood vessels 
are closely associated with insulin+ cells inside the engineered stomach sphere (G). Scale 
bars, 100 μm. Blue channel, DAPI.
See also Figure S7.
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